DK0650960T3 - Substituerede heterocykliske carboxylsyreamid-estere, deres fremstilling og deres anvendelse som lægemidler. - Google Patents
Substituerede heterocykliske carboxylsyreamid-estere, deres fremstilling og deres anvendelse som lægemidler.Info
- Publication number
- DK0650960T3 DK0650960T3 DK94117017.7T DK94117017T DK0650960T3 DK 0650960 T3 DK0650960 T3 DK 0650960T3 DK 94117017 T DK94117017 T DK 94117017T DK 0650960 T3 DK0650960 T3 DK 0650960T3
- Authority
- DK
- Denmark
- Prior art keywords
- preparation
- drugs
- carboxylic acid
- acid amide
- substituted heterocyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4337270A DE4337270A1 (de) | 1993-11-02 | 1993-11-02 | Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel |
| DE19944434288 DE4434288A1 (de) | 1994-09-26 | 1994-09-26 | Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0650960T3 true DK0650960T3 (da) | 1997-09-01 |
Family
ID=25930886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK94117017.7T DK0650960T3 (da) | 1993-11-02 | 1994-10-27 | Substituerede heterocykliske carboxylsyreamid-estere, deres fremstilling og deres anvendelse som lægemidler. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US5658933A (es) |
| EP (1) | EP0650960B1 (es) |
| JP (1) | JPH07224039A (es) |
| KR (1) | KR950014069A (es) |
| CN (1) | CN1084736C (es) |
| AT (1) | ATE149485T1 (es) |
| AU (1) | AU689135B2 (es) |
| CA (1) | CA2134865A1 (es) |
| CZ (1) | CZ287767B6 (es) |
| DE (1) | DE59401923D1 (es) |
| DK (1) | DK0650960T3 (es) |
| ES (1) | ES2101420T3 (es) |
| GR (1) | GR3023177T3 (es) |
| HK (1) | HK1006712A1 (es) |
| IL (1) | IL111455A0 (es) |
| NO (1) | NO302028B1 (es) |
| NZ (1) | NZ264822A (es) |
| PH (1) | PH31264A (es) |
| PL (1) | PL179687B1 (es) |
| RU (1) | RU2145959C1 (es) |
| TW (1) | TW330202B (es) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6046219A (en) * | 1995-01-20 | 2000-04-04 | Cornell Research Foundation, Inc. | Method for the treatment of conditions mediated by collagen formation together with cell proliferation by application of inhibitors of protein hydroxylation |
| IL135495A (en) * | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid |
| WO1997041103A1 (de) * | 1996-04-30 | 1997-11-06 | Hoechst Aktiengesellschaft | 3-alkoxypyridin-2-carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel |
| JPH1067674A (ja) * | 1996-06-19 | 1998-03-10 | Advanced Sukin Res Kenkyusho:Kk | 細胞外マトリツクスの異常蓄積抑制剤 |
| DE19746287A1 (de) * | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| WO2000026191A1 (fr) * | 1998-11-04 | 2000-05-11 | Meiji Seika Kaisha, Ltd. | Derives de picolinamide et pesticides contenant ces derives comme ingredient actif |
| FR2803592A1 (fr) * | 2000-01-06 | 2001-07-13 | Aventis Cropscience Sa | Nouveaux derives de l'acide 3-hydroxypicolinique, leur procede de preparation et compositions fongicides les contenant. |
| WO2001092258A1 (en) * | 2000-05-30 | 2001-12-06 | Neurogen Corporation | Imidazoloisoquinolines |
| CN101664551B (zh) * | 2001-12-06 | 2013-08-14 | 法布罗根股份有限公司 | 低氧诱导因子(HIF)α的稳定化 |
| EP2295060B1 (en) | 2001-12-06 | 2018-10-31 | Fibrogen, Inc. | Treatment or prevention of ischemic or hypoxic conditions |
| CA3094774A1 (en) * | 2001-12-06 | 2003-07-03 | Fibrogen, Inc. | Use of hif prolyl hydroxylase inhibitors for treating neurological disorders |
| US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
| US7618940B2 (en) * | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
| BRPI0411055B1 (pt) * | 2003-06-06 | 2018-08-21 | Fibrogen, Inc | Compostos de heteroarilas contendo nitrogênio. seus usos no aumento da eritropoietina endógena, composição farmacêutica que os compreende e método in vitro de inibição da atividade da enzima hidrolase |
| US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| JP4792048B2 (ja) * | 2005-03-02 | 2011-10-12 | ファイブロゲン インコーポレイティッド | チエノピリジン化合物およびその使用方法 |
| US20060276477A1 (en) * | 2005-06-06 | 2006-12-07 | Fibrogen, Inc. | Treatment method for anemia |
| AU2006259352A1 (en) | 2005-06-15 | 2006-12-28 | Fibrogen, Inc. | Use of HIF 1alfa modulators for treatment of cancer |
| MX2008009581A (es) | 2006-01-27 | 2009-01-07 | Fibrogen Inc | Compuestos de cianoisoquinolina que estabilizan el factor inducible hipoxia (fih). |
| MX2008010671A (es) * | 2006-02-21 | 2008-10-01 | Amgen Inc | Derivados de cinolina como inhibidores de fosfodiesterasa 10. |
| EP1996574A1 (en) * | 2006-03-08 | 2008-12-03 | Amgen Inc. | Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors |
| JP5111491B2 (ja) | 2006-04-04 | 2013-01-09 | フィブロジェン， インコーポレイテッド | ピロロ−およびピラゾロ−ピリミジン化合物、およびそれらの使用方法 |
| AU2013231191B2 (en) * | 2006-06-23 | 2015-09-03 | Glaxosmithkline Llc | Prolyl hydroxylase inhibitors |
| AR061570A1 (es) | 2006-06-23 | 2008-09-03 | Smithkline Beecham Corp | Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto |
| EP2327696A1 (en) | 2006-06-26 | 2011-06-01 | Warner Chilcott Company, LLC | Prolyl hydroxylase inhibitors and methods of use |
| JP5352454B2 (ja) * | 2006-06-28 | 2013-11-27 | サノフイ | Ｃｘｃｒ２アンンタゴニスト |
| WO2008000410A1 (en) * | 2006-06-30 | 2008-01-03 | Sanofi-Aventis | Cxcr2 inhibitors |
| TW200845991A (en) * | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: hydroxylase inhibitors |
| WO2009002533A1 (en) | 2007-06-27 | 2008-12-31 | The Brigham And Women's Hospital, Inc. | Inflammatory bowel disease therapies |
| EP2370422B1 (en) | 2008-11-14 | 2019-06-05 | Fibrogen, Inc. | Thiochromene derivatives as hif hydroxylase inhibitors |
| WO2010093727A1 (en) * | 2009-02-10 | 2010-08-19 | Janssen Pharmaceutica Nv | Quinazolinones as prolyl hydroxylase inhibitors |
| NZ600400A (en) * | 2009-11-06 | 2014-09-26 | Aerpio Therapeutics Inc | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha |
| US8247436B2 (en) * | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| EP2670750B1 (en) | 2011-02-02 | 2016-09-14 | Fibrogen, Inc. | Naphthyridine derivatives as inhibitors of hypoxia inducible factor |
| NO2686520T3 (es) | 2011-06-06 | 2018-03-17 | ||
| MX2013014310A (es) * | 2011-06-06 | 2014-01-23 | Akebia Therapeutics Inc | Compuestos y composiciones para estabilizar el factor-2 alfa inducible por hipoxia como un metodo para tratar el cancer. |
| BR112014009910B1 (pt) | 2011-10-25 | 2020-06-30 | Janssen Pharmaceutica N.V. | sal di-hidrato de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico, composição farmacêuticae pomada tópica |
| AU2013229922B2 (en) | 2012-03-09 | 2017-09-28 | Fibrogen, Inc. | 4 -hydroxy- isoquinoline compounds as HIF hydroxylase inhibitors |
| US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| RS57795B1 (sr) | 2012-07-16 | 2018-12-31 | Fibrogen Inc | Kristalni oblici inhibitora prolil hidroksilaze |
| HUE034409T2 (en) | 2012-07-16 | 2018-02-28 | Fibrogen Inc | Process for the preparation of isoquinoline compounds |
| RU2666144C2 (ru) | 2013-01-24 | 2018-09-06 | Фиброген, Инк. | Кристаллические формы { [1-циано-5-(4-хлорофенокси)-4-гидроксиизохинолин-3-карбонил]-амино} -уксусной кислоты |
| NZ753905A (en) | 2013-06-13 | 2020-07-31 | Akebia Therapeutics Inc | Compositions and methods for treating anemia |
| TWI788702B (zh) | 2013-11-15 | 2023-01-01 | 美商阿克比治療有限公司 | {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式，其組合物及用途 |
| BR112017013105A2 (pt) * | 2014-12-30 | 2017-12-26 | Dow Agrosciences Llc | picolinamidas com atividade fungicida |
| AU2016209126A1 (en) | 2015-01-23 | 2017-08-10 | Akebia Therapeutics, Inc. | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
| CN106146395B (zh) * | 2015-03-27 | 2019-01-01 | 沈阳三生制药有限责任公司 | 3-羟基吡啶化合物、其制备方法及其制药用途 |
| US11324734B2 (en) | 2015-04-01 | 2022-05-10 | Akebia Therapeutics, Inc. | Compositions and methods for treating anemia |
| US11713298B2 (en) | 2018-05-09 | 2023-08-01 | Akebia Therapeutics, Inc. | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid |
| CN113767089A (zh) * | 2019-04-26 | 2021-12-07 | 株式会社钟化 | 伐度司他中间体的制造方法 |
| CN110305143B (zh) * | 2019-07-19 | 2021-03-09 | 济南新科医药科技有限公司 | 一种呋喃[2，3-c]并吡啶衍生物及其制备方法和用途 |
| US11524939B2 (en) | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4015255A1 (de) * | 1990-05-12 | 1991-11-14 | Hoechst Ag | Oxalyl-aminosaeurederivate, verfahren zu ihrer herstellung und ihrer verwendung als arzneimittel zur inhibierung der prolyl-hydroxylase |
| US5192773A (en) * | 1990-07-02 | 1993-03-09 | Vertex Pharmaceuticals, Inc. | Immunosuppressive compounds |
| EP0541042A1 (de) * | 1991-11-05 | 1993-05-12 | Hoechst Aktiengesellschaft | Pyridin-2,4- und 2,5-dicarbonsäureamide und deren Derivate, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel |
| TW352384B (en) * | 1992-03-24 | 1999-02-11 | Hoechst Ag | Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals |
-
1994
- 1994-10-27 DE DE59401923T patent/DE59401923D1/de not_active Expired - Fee Related
- 1994-10-27 AT AT94117017T patent/ATE149485T1/de not_active IP Right Cessation
- 1994-10-27 DK DK94117017.7T patent/DK0650960T3/da active
- 1994-10-27 ES ES94117017T patent/ES2101420T3/es not_active Expired - Lifetime
- 1994-10-27 EP EP94117017A patent/EP0650960B1/de not_active Expired - Lifetime
- 1994-10-28 PH PH49264A patent/PH31264A/en unknown
- 1994-10-28 PL PL94305647A patent/PL179687B1/pl unknown
- 1994-10-30 IL IL11145594A patent/IL111455A0/xx unknown
- 1994-10-31 NZ NZ264822A patent/NZ264822A/en unknown
- 1994-10-31 AU AU77566/94A patent/AU689135B2/en not_active Ceased
- 1994-10-31 US US08/332,824 patent/US5658933A/en not_active Expired - Lifetime
- 1994-11-01 NO NO944161A patent/NO302028B1/no not_active IP Right Cessation
- 1994-11-01 CA CA002134865A patent/CA2134865A1/en not_active Abandoned
- 1994-11-01 CZ CZ19942682A patent/CZ287767B6/cs not_active IP Right Cessation
- 1994-11-01 RU RU94040163A patent/RU2145959C1/ru active
- 1994-11-02 JP JP6292031A patent/JPH07224039A/ja not_active Abandoned
- 1994-11-02 CN CN94117622A patent/CN1084736C/zh not_active Expired - Fee Related
- 1994-11-02 KR KR1019940028870A patent/KR950014069A/ko not_active Application Discontinuation
- 1994-12-05 TW TW083111258A patent/TW330202B/zh active
-
1997
- 1997-04-18 GR GR970400836T patent/GR3023177T3/el unknown
-
1998
- 1998-06-22 HK HK98105874A patent/HK1006712A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR950014069A (ko) | 1995-06-15 |
| GR3023177T3 (en) | 1997-07-30 |
| DE59401923D1 (de) | 1997-04-10 |
| TW330202B (en) | 1998-04-21 |
| EP0650960A1 (de) | 1995-05-03 |
| PL179687B1 (pl) | 2000-10-31 |
| ES2101420T3 (es) | 1997-07-01 |
| CA2134865A1 (en) | 1995-05-03 |
| RU94040163A (ru) | 1997-02-20 |
| US5658933A (en) | 1997-08-19 |
| NO944161L (no) | 1995-05-03 |
| NO944161D0 (no) | 1994-11-01 |
| AU7756694A (en) | 1995-05-18 |
| NZ264822A (en) | 1997-02-24 |
| ATE149485T1 (de) | 1997-03-15 |
| PL305647A1 (en) | 1995-05-15 |
| EP0650960B1 (de) | 1997-03-05 |
| CN1084736C (zh) | 2002-05-15 |
| CZ287767B6 (en) | 2001-01-17 |
| PH31264A (en) | 1998-06-18 |
| JPH07224039A (ja) | 1995-08-22 |
| RU2145959C1 (ru) | 2000-02-27 |
| CZ268294A3 (en) | 1995-05-17 |
| HK1006712A1 (en) | 1999-03-12 |
| NO302028B1 (no) | 1998-01-12 |
| CN1107144A (zh) | 1995-08-23 |
| IL111455A0 (en) | 1994-12-29 |
| AU689135B2 (en) | 1998-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0650960T3 (da) | Substituerede heterocykliske carboxylsyreamid-estere, deres fremstilling og deres anvendelse som lægemidler. | |
| NO944162L (no) | Substituerte heterosykliske karboksylsyreamider, deres fremstilling og deres anvendelse som legemiddel | |
| DK0661269T3 (da) | Substituerede heterocykliske carboxylsyreamider, deres fremstilling og anvendelse som lægemidler. | |
| HUT70836A (en) | 1-h-indole-3-acetamide spla2 inhibitors, process for producing them and pharmaceutical compositions comprising same compounds | |
| IL109309A (en) | 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them | |
| NO951147L (no) | Substituerte heterocykliske karboksylsyreamidestere, deres fremstilling og deres anvendelse som legemiddel | |
| AU686104B2 (en) | Substituted amidinonaphthyl ester derivatives | |
| MY112414A (en) | Substituted heterocyclic carboxamide esters, their preparation and their use as pharmaceuticals |